Some Studies of the Stability of Compounded Cefazolin Ophthalmic Solution
Author(s): Kommanaboyina Brahmaiah, Lindauer Richard F, Rhodes Christopher T, Grady Lee T
Issue: Mar/Apr 2000 - Compounding for Diabetes Patients
View All Articles in Issue
Page(s): 146-149
Download in electronic PDF format for $75
Abstract: The chemical stability of three compounded batches of cefazolin
ophthalmic solution was monitored by a stability-indicating
high-performance liquid chromatography assay. The
degradation was governed by first-order kinetics, and the effect
of temperature on reaction rate was in accordance with the
Arrhenius equation at and above 17°C. Although the stability
of all three batches was essentially the same, buffering the formulations
may be useful. Even using a most cautious and conservative
approach to the assignment of a beyond-use date for
this type of product, it appears that, if the product is stored at
controlled room temperature, a beyond-use date of six days
would be fully justifiable. If the product is stored in a refrigerator,
then a beyond-use date of 14 days could be assigned.
Related Keywords:
cefazolin, stability, compound, ophthalmic, buffer, pH, degradation
| Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Some Studies of the Stability of Compounded Cefazolin Ophthalmic Solution
Kommanaboyina Brahmaiah, Lindauer Richard F, Rhodes Christopher T, Grady Lee T
|
Mar/Apr 2000
Pg. 146-149
|
Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R, Newton Gail D
|
May/Jun 2004
Pg. 181-185
|
Basics of Sterile Compounding: Ophthalmic Preparations, Part 1: Ophthalmic Solutions
Allen Loyd V Jr
|
Sep/Oct 2016
Pg. 399-404
|
Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
|
Jul/Aug 2004
Pg. 269-274
|
pH Stability of Injectable Fentanyl, Bupivacaine, or Clonidine Solution or a Ternary Mixture in 0.9% Sodium Chloride in Two Types of Polypropylene Syringes
Jappinen Annaliisa L, Kokki H, Rasi A S, Naaranlahti Toivo J
|
Nov/Dec 2002
Pg. 471-474
|
Three Fortified Ophthalmic Solutions: Amikacin 5% Ophthalmic Solution; Ceftazidime 5% Ophthalmic Solution; Vancomycin 5% Ophthalmic Solution
Allen Loyd V Jr
|
Sep/Oct 2010
Pg. 421
|
Cefazolin Ophthalmic Solution, USP 0.35- mg/mL
Allen Loyd V Jr
|
Jul/Aug 2001
Pg. 300
|
Basics of Sterile Compounding: Ophthalmic Preparations, Part 2: Suspensions and Ointments
Allen Loyd V Jr
|
Nov/Dec 2016
Pg. 495-500
|
Formulation and Stability of Solutions
Akers Michael J
|
Jan/Feb 2016
Pg. 41-45
|
Basics of Compounding for Disorders of the External Ear
Allen Loyd V Jr
|
Jan/Feb 2004
Pg. 46-48
|
Chemical Stability of Cefazolin Sodium after Reconstituting in 0.9% Sodium Chloride Injection and Storage in Polypropylene Syringes for Pediatric Use
Gupta Vishnu D
|
Mar/Apr 2003
Pg. 152-154
|
Cefazolin 250-mg/mL Injection
Allen Loyd V Jr
|
Nov/Dec 2013
Pg. 499
|
Stability of 5-Fluorouracil in an Extemporaneously Compounded Ophthalmic Solution
Fuhrman L Clifton, Godwin Donald A, Davis R Alan
|
Jul/Aug 2000
Pg. 320-323
|
Basics of Compounding for Cold Sores or Fever Blisters
Allen Loyd V Jr
|
May/Jun 2004
Pg. 206-209
|
The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013
Lutz Eugene, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, Llambí Francesc
|
Jan/Feb 2014
Pg. 6-12
|
Basics of Compounding: Clinical Studies
Allen Loyd V Jr
|
Nov/Dec 2002
Pg. 443-447
|
Stability of Amphotericin B in 5% Dextrose Ophthalmic Solution
Peyron Florence, Elias R, Ibrahim E, Amirat-Combralier V, Bues-Charbit M, Balansard G
|
Jul/Aug 1999
Pg. 316-320
|
Basics of Compounding: Compounding Irrigation Solutions for Sterile and Nonsterile Preparations
Allen Loyd V Jr
|
Nov/Dec 2017
Pg. 481-486
|
Cyclopentolate Hydrochloride 0.5%, Phenylephrine HCl 2.5%, and Tropicamide 0.5% Ophthalmic Solution
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 324
|
Quality Control: Lessons Learned from a Trimix Stability Study in a 503A Compounding Pharmacy
Rhoads Rick
|
Mar/Apr 2018
Pg. 129-134
|
| Return to Top |
